Table 1.
Patient and transplant characteristics.
| Patient Characteristics | Nº (%) |
|---|---|
| Age at transplant | |
| Median (range), years | 53 (38–62) |
| Sex | |
| Male/Female | 16 (73%)/6 (27%) |
| Diagnosis | |
| Acute myeloblastic leukemia | 12 (54%) |
| Myeloproliferative disorders | 5 (23%) |
| Myelodysplastic syndrome | 2 (9%) |
| Non-Hodgkin lymphoma | 2 (9%) |
| Acute lymphoblastic leukemia | 1 (5%) |
| Disease status | |
| First complete remission | 9 (41%) |
| >Second complete remission | 3 (14%) |
| Partial remission | 6 (27%) |
| Refractory disease/Stable disease | 4 (18%) |
| Disease Risk Index | |
| Very high | 1 (5%) |
| High | 8 (36%) |
| Intermediate | 6 (27%) |
| Low | 3 (14%) |
| Unclassifiable | 4 (18%) |
| Conditioning intensity | |
| RIC | 11 (50%) |
| MAC | 11 (50%) |
| Detailed information on Conditioning Regimens | |
| Reduced-intensity regimens | |
| FLAG/IDA/Bu2 | 2 (9%) |
| FLAG/IDA/Treo | 2 (9%) |
| FLAG/Bu | 1 (5%) |
| Flu + Bu (9.6 mg/kg) | 6 (27%) |
| Myeloablative regimens | |
| Flu + Bu (12.8 mg/kg) | 8 (36%) |
| Flu + TBI (12Gy) | 2 (9%) |
| Flu/Treo | 1 (5%) |
| Hematopoietic cell transplantation-comorbidity index | |
| ≤3 | 8 (36%) |
| >3 | 14 (64%) |
| Karnofsky performance status | |
| ≤80 | 15 (32%) |
| Donor type | |
| Match related donor | 8 (36%) |
| Match unrelated donor | 14 (64%) |
| Donor/recipient gender mismatch | |
| Female/Male | 6 (27%) |
| Dose of CD34+ cells (×106/kg), median (range) | 6.25 (4.96–7.18) |
| Cytomegalovirus risk | |
| High risk | 3 (14%) |
| Intermediate risk | 17 (77%) |
| Prophylaxis with letermovir | 18 (82%) |
FLAG/IDA/Bu, fludarabine, cytosine arabinoside, idarubicin, busulfan; FLAG/IDA/Treo, fludarabine, cytosine arabinoside, idarubicin, treosulfan; FLAG/Bu, fludarabine, cytosine arabinoside, busulfan; Flu, fludarabine; TBI, total body irradiation; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning.